Which condition is a potential adverse effect of Clopidogrel?

Clopidogrel, an antiplatelet agent, is known for its potential to cause Thrombotic Thrombocytopenic Purpura (TTP), a rare but serious blood disorder characterized by a combination of symptoms including thrombocytopenia (low platelet count), hemolytic anemia, neurological deficits, and renal impairment. TTP is thought to be related to the inhibition of the ADP receptor on platelets, which can lead to excessive clotting under certain circumstances.

The occurrence of TTP is particularly concerning because it can lead to severe health complications if not recognized and treated promptly. It underscores the importance of monitoring patients on Clopidogrel for any signs of hematological abnormalities.

The other options presented, such as neutropenia, heart attack, and stroke, are either not commonly associated directly with Clopidogrel or are more consequences of the disease conditions themselves rather than direct adverse effects of the medication. Neutropenia can occur with certain drugs but is not a known adverse effect of Clopidogrel. While Clopidogrel is designed to prevent heart attacks and strokes, these events can still happen in the context of underlying cardiovascular disease rather than being a direct side effect of the drug.